NO992063L - Benzoksazolderivat med affinitet til bindingssteder pÕ aminosyrereseptorer - Google Patents

Benzoksazolderivat med affinitet til bindingssteder pÕ aminosyrereseptorer

Info

Publication number
NO992063L
NO992063L NO992063A NO992063A NO992063L NO 992063 L NO992063 L NO 992063L NO 992063 A NO992063 A NO 992063A NO 992063 A NO992063 A NO 992063A NO 992063 L NO992063 L NO 992063L
Authority
NO
Norway
Prior art keywords
amino acid
affinity
binding sites
acid receptors
benzoxazole derivative
Prior art date
Application number
NO992063A
Other languages
English (en)
Other versions
NO992063D0 (no
Inventor
Cher Helmut Pr
Rudolf Gottschlich
Joachim Leibrock
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO992063D0 publication Critical patent/NO992063D0/no
Publication of NO992063L publication Critical patent/NO992063L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelsen 6-{3-[4-(4- fluorbenzyl)-piperidin-1-yl]- prop±onyl}-3H-benzoksazol-2-on med formel (I) samt dens fysiologisk akseptable salter kan anvendes som eksitatoriske aminosyreantagonister for bekjempelse av neurodegenerative sykdommer, særlig cerebrovaskulære sykdommer, epilepsi, schizofreni, Alzheimers, Parkinsons hhv. Huntingtons sykdom, cerebrale iskemier, infarkt eller psykoser.
NO992063A 1996-10-30 1999-04-29 Benzoksazolderivat med affinitet til bindingssteder pÕ aminosyrereseptorer NO992063L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19643790A DE19643790A1 (de) 1996-10-30 1996-10-30 Benzoxazol-Derivat
PCT/EP1997/005590 WO1998018793A1 (de) 1996-10-30 1997-10-10 Benzoxazolderivat mit affinität zu bindungsstellen von aminosäurerezeptoren

Publications (2)

Publication Number Publication Date
NO992063D0 NO992063D0 (no) 1999-04-29
NO992063L true NO992063L (no) 1999-04-29

Family

ID=7809592

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992063A NO992063L (no) 1996-10-30 1999-04-29 Benzoksazolderivat med affinitet til bindingssteder pÕ aminosyrereseptorer

Country Status (16)

Country Link
EP (1) EP0938485A1 (no)
JP (1) JP2001502713A (no)
KR (1) KR20000052876A (no)
CN (1) CN1235604A (no)
AR (1) AR008512A1 (no)
AU (1) AU4946597A (no)
BR (1) BR9712577A (no)
CA (1) CA2270359A1 (no)
CZ (1) CZ147999A3 (no)
DE (1) DE19643790A1 (no)
HU (1) HUP9904547A3 (no)
NO (1) NO992063L (no)
PL (1) PL332771A1 (no)
SK (1) SK53699A3 (no)
WO (1) WO1998018793A1 (no)
ZA (1) ZA979725B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725541D0 (en) * 1997-12-02 1998-02-04 Pharmacia & Upjohn Spa Amino-benzothiazole derivatives
DE19812331A1 (de) * 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
US6476041B1 (en) * 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
DE10120159A1 (de) * 2001-04-25 2002-10-31 Merck Patent Gmbh NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen
KR100890676B1 (ko) 2001-07-24 2009-03-26 리히데 게데온 베기에스제티 기아르 알티 신규한 카르복시산 아미드 화합물
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
SG10201800159QA (en) 2011-11-22 2018-02-27 Univ California Cysteamine and/or cystamine for treating ischemic injury

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE174915T1 (de) * 1994-10-31 1999-01-15 Merck Patent Gmbh Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren

Also Published As

Publication number Publication date
DE19643790A1 (de) 1998-05-07
NO992063D0 (no) 1999-04-29
PL332771A1 (en) 1999-10-11
KR20000052876A (ko) 2000-08-25
HUP9904547A2 (hu) 2000-12-28
CA2270359A1 (en) 1998-05-07
EP0938485A1 (de) 1999-09-01
WO1998018793A1 (de) 1998-05-07
SK53699A3 (en) 2000-03-13
CN1235604A (zh) 1999-11-17
ZA979725B (en) 1998-05-22
CZ147999A3 (cs) 1999-08-11
BR9712577A (pt) 1999-10-19
HUP9904547A3 (en) 2001-01-29
AR008512A1 (es) 2000-01-19
AU4946597A (en) 1998-05-22
JP2001502713A (ja) 2001-02-27

Similar Documents

Publication Publication Date Title
NO20004668L (no) 1-(3-heteroarylpropyl- eller -prop-2-enyl)-4- benzylpiperidiner anvendt som NMDA-reseptorantagonister
DE50313528D1 (de) Substituierte indole und deren verwendung als 5ht-wiederaufnahme inhibitoren und als 5ht liganden
Gaetz et al. Dynein/dynactin regulate metaphase spindle length by targeting depolymerizing activities to spindle poles
Hawasli et al. Alternative roles for Cdk5 in learning and synaptic plasticity
PH12018500940A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
DE59510635D1 (de) Verwendung heterocyclischer verbindungen als dopamin-d 3 liganden
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
ATE300052T1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
JP2002535394A5 (no)
Krivoy et al. The possible involvement of metabotropic glutamate receptors in schizophrenia
CN114728071A (zh) 用于降解tau蛋白聚集体的化合物及其用途
AU4007900A (en) Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
ATE393781T1 (de) Somatostatin analoge, deren radiomarkierte derivate und deren verwendung
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
EP1044605A4 (en) GENUTUTED ANIMALS
Yakout et al. Tau regulates Arc stability in neuronal dendrites via a proteasome-sensitive but ubiquitin-independent pathway
BR9712577A (pt) Derivado de benzoxazola
Wustrow et al. Aminopyrimidines with high affinity for both serotonin and dopamine receptors
ATE529114T1 (de) Tetrahydrobenzazepine und ihre verwendung in der modulation des dopamin-d3-rezeptors
DK2882742T3 (en) Arylethynylpyrimidiner
ATE486962T1 (de) Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
WO2007008514A3 (en) Inhibitors of glycogen synthase kinase 3
CN100528871C (zh) 用作腺苷受体的配体的苯并噻唑衍生物
Ogawa et al. Change of central cholinergic receptors following lesions of nucleus basalis magnocellularis in rats: search for an imaging index suitable for the early detection of Alzheimer's disease
Lu et al. Targeting TMEM175 in lysosomal physiology and human diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application